Melanoma Clinical Trial

Tissue Procurement Substudy for Participants in Study CP-MGA271-01

Summary

The purpose of this study is to gain a better understanding about how the study drug MGA271 works. No test drug will be given in this study. Patients with easily accessible tumors at the screening visit for participation in Study CP-MGA271-01 will be asked to participate in this substudy. Patients will undergo two excisional biopsies, punch biopsies, or core needle biopsies.

View Full Description

Full Description

Patients with easily accessible tumors (generally, metastatic deposits involving skin, subcutaneous tissues, or peripheral lymph node whose excision would not require general anaesthesia or the invasion of a body cavity) at the screening visit for participation in Study CP-MGA271-01 (the main study) will be asked to participate in this substudy. After providing appropriate informed consent, patients will undergo excisional biopsy, punch biopsy, or core needle biopsy of the accessible tumor prior to receiving study drug in the main study and then again after the first cycle of study drug is completed.

Some of the biopsy tissue will be sent to a central laboratory for research purposes. The central lab will analyze the tissue to see what effects that the study drug might have on tumors.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Qualified, by meeting all inclusion and exclusion criteria, for participation in Study CP-MGA271-01.
Must have provided informed consent to participate in Study CP-MGA271-01.
Must have accessible tumors (generally speaking, metastatic deposits involving skin, subcutaneous tissue, or peripheral lymph node whose excision, punch biopsy, or core needle biopsy would not require general anaesthesia or the invasion of a body cavity).
Willing to undergo two minor surgical procedures with no expectation of personal benefit
Have provided Informed Consent for this substudy as indicated by a signature on an approved consent document obtained from the patient or his/her legally authorized representative

Exclusion Criteria:

Any medical condition that would contraindicate the use of local or locoregional anaesthesia, or conscious sedation for the intended minor surgical procedure.
Any medical condition (eg. skin disease or bleeding diathesis) that would hinder wound healing following a minor surgical procedure.
Dementia or altered mental status that would preclude understanding and rendering of informed consent.

Study is for people with:

Melanoma

Phase:

Phase 1

Estimated Enrollment:

6

Study ID:

NCT01918930

Recruitment Status:

Terminated

Sponsor:

MacroGenics

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 7 Locations for this study

See Locations Near You

UCLA Hematology-Oncology Clinic
Los Angeles California, 90095, United States
Moffitt Cancer Center
Tampa Florida, 33612, United States
The University of Chicago
Chicago Illinois, 60637, United States
Massachusetts General Hospital Cancer Center
Boston Massachusetts, 02114, United States
Carolina BioOncology Institute
Huntersville North Carolina, 28078, United States
Hospital of the University of Pennsylvania/Abramson Cancer Center
Philadelphia Pennsylvania, 19104, United States
Sarah Cannon Research Institute
Nashville Tennessee, 37203, United States

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Phase:

Phase 1

Estimated Enrollment:

6

Study ID:

NCT01918930

Recruitment Status:

Terminated

Sponsor:


MacroGenics

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider